The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Treatment of HER2-positive breast cancer
Open accessAbstract
The human epidermal growth factor receptor 2 gene (HER2) is overexpressed and/or amplified in ~15% of breast cancer patients and was identified a quarter century ago as a marker of poor prognosis. By 1998, antibody therapy targeting the HER2 pathway was shown to demonstrably improve progression-free and overall survival in metastatic disease, and in 2005 evidence of improvement in disease-free and overall survival from the first generation of trastuzumab adjuvant trials became available. However, not all patients with HER2 overexpression benefit from trastuzumab. Second-generation studies in metastatic disease led to the approval of several new HER2-targeted therapies using small molecule tyrosine kinase inhibitors such as lapatinib, new HER2/HER3 antibodies such as pertuzumab, and the new antibody chemotherapy conjugate ado-trastuzumab emtansine. These successes supported the launch of second-generation adjuvant trials testing single and dual HER2-targeted agents, administered concomitantly or sequentially with chemotherapy that will soon complete accrual. HER2-positive breast cancer in the setting of HER2-targeted therapy is no longer associated with poor prognosis, and recent guidance by the US Food and Drug Administration suggests that pathologic response to HER2-targeted therapy given preoperatively may allow an earlier assessment of their clinical benefit in the adjuvant setting. An adjuvant trial of trastuzumab in patient whose tumors express normal levels of HER2 and trials of single/dual HER2-targeting without chemotherapy are also ongoing. In this article, we review the current data on the therapeutic management of HER2-positive breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 2×
“The HER2-positive phenotype observed in about 15% of patients is of great scientific interest as HER2 overexpression is associated with worse clinical outcome (worse prognosis) in the absence of therapy [2].”
BackgroundSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 3×
“To minimize the cardiotoxicity risk [4], many investigators favor non-anthracycline trastuzumab regimens as tested in the adjuvant BCIRG 006 trial [7].”
BackgroundInfluentialIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Self-citationWolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Self-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 2×
“Data from metastatic trials of pertuzumab [32] and adotrastuzumab emtansine [47] have now led to ongoing adjuvant trials.”
BackgroundLapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,460
Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2013-0953-sa · Cited by 1,762
Self-citationTargeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., Gómez, H., Dinh, P., Fauria, K., Van Dooren, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,317
Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., Tausch, C., Seo, J. H., Tsai, Y.-F., Ratnayake, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt182 · Cited by 1,264
Gianni, L., Eiermann, W., Semiglazov, V., Manikhas, A., Lluch, A., Tjulandin, S., Zambetti, M., Vazquez, F., Byakhow, M., Lichinitser, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61964-4 · Cited by 1,255
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., Ellis, C., Casey, M., Vukelja, S., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 942
Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 843
Cameron, D., Casey, M., Press, M., Lindquist, D., Pienkowski, T., Romieu, C. G., Chan, S., Jagiello-Gruszfeld, A., Kaufman, B., Crown, J., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9885-0 · Cited by 794
Burris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., Girish, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5865 · Cited by 764
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kaufman, P. A., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0868 · Cited by 717
von Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
Rabindran, S. K., Discafani, C. M., Rosfjord, E. C., Baxter, M., Floyd, M. B., Golas, J., Hallett, W. A., Johnson, B. D., Nilakantan, R., Overbeek, E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2868 · Cited by 639
Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., & Hasmann, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4597 · Cited by 622
Gianni, L., Dafni, U., Gelber, R. D., Azambuja, E., Muehlbauer, S., Goldhirsch, A., Untch, M., Smith, I., Baselga, J., Jackisch, C., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70033-x · Cited by 612
Nahta, R., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 607
Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J.-H., Sliwkowski, M. X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2071 · Cited by 595
Untch, M., Rezai, M., Loibl, S., Fasching, P. A., Huober, J., Tesch, H., Bauerfeind, I., Hilfrich, J., Eidtmann, H., Gerber, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8451 · Cited by 556
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G., Aktan, G., Ellis, C., Florance, A., Vukelja, S., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6725 · Cited by 547
Burstein, H. J., Sun, Y., Dirix, L. Y., Jiang, Z., Paridaens, R., Tan, A. R., Awada, A., Ranade, A., Jiao, S., Schwartz, G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8707 · Cited by 522
HER-2 gene amplification can be acquired as breast cancer progresses
Meng, S., Tripathy, D., Shete, S., Ashfaq, R., Haley, B., Perkins, S., Beitsch, P., Khan, A., Euhus, D., Osborne, C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402993101 · Cited by 508
Untch, M., Fasching, P. A., Konecny, G. E., Hasmüller, S., Lebeau, A., Kreienberg, R., Camara, O., Müller, V., du Bois, A., Kühn, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4930 · Cited by 506
Goldhirsch, A., Gelber, R. D., Piccart-Gebhart, M. J., de Azambuja, E., Procter, M., Suter, T. M., Jackisch, C., Cameron, D., Weber, H. A., Heinzmann, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61094-6 · Cited by 497
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Robert, N., Leyland-Jones, B., Asmar, L., Belt, R., Ilegbodu, D., Loesch, D., Raju, R., Valentine, E., Sayre, R., Cobleigh, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1764 · Cited by 479
Buzdar, A. U., Valero, V., Ibrahim, N. K., Francis, D., Broglio, K. R., Theriault, R. L., Pusztai, L., Green, M. C., Singletary, S. E., Hunt, K. K., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1345 · Cited by 475
Gonzalez-Angulo, A. M., Litton, J. K., Broglio, K. R., Meric-Bernstam, F., Rakkhit, R., Cardoso, F., Peintinger, F., Hanrahan, E. O., Sahin, A., Guray, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2025 · Cited by 467
Joensuu, H., Bono, P., Kataja, V., Alanko, T., Kokko, R., Asola, R., Utriainen, T., Turpeenniemi-Hujanen, T., Jyrkkiö, S., Möykkynen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4577 · Cited by 458
Untch, M., Loibl, S., Bischoff, J., Eidtmann, H., Kaufmann, M., Blohmer, J.-U., Hilfrich, J., Strumberg, D., Fasching, P. A., Kreienberg, R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70397-7 · Cited by 451
HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
Paik, S., Kim, C., & Wolmark, N. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0801440 · Cited by 426
Di Leo, A., Gomez, H. L., Aziz, Z., Zvirbule, Z., Bines, J., Arbushites, M. C., Guerrera, S. F., Koehler, M., Oliva, C., Stein, S. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2578 · Cited by 418
Krop, I. E., LoRusso, P., Miller, K. D., Modi, S., Yardley, D., Rodriguez, G., Guardino, E., Lu, M., Zheng, M., Girish, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5902 · Cited by 366
Baselga, J., Cortés, J., Im, S.-A., Clark, E., Ross, G., Kiermaier, A., & Swain, S. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5384 · Cited by 364
Guarneri, V., Frassoldati, A., Bottini, A., Cagossi, K., Bisagni, G., Sarti, S., Ravaioli, A., Cavanna, L., Giardina, G., Musolino, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0823 · Cited by 360
Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
Prowell, T. M., & Pazdur, R. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1205737 · Cited by 342
Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., & Slamon, D. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201222 · Cited by 332
Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood
Higgins, M. J., Jelovac, D., Barnathan, E., Blair, B., Slater, S., Powers, P., Zorzi, J., Jeter, S. C., Oliver, G. R., Fetting, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2696 · Cited by 309
Self-citationComparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
Gancberg, D., Di Leo, A., Cardoso, F., Rouas, G., Pedrocchi, M., Paesmans, M., Verhest, A., Bernard-Marty, C., Piccart, M. J., & Larsimont, D. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf252 · Cited by 309
Ryan, Q., Ibrahim, A., Cohen, M. H., Johnson, J., Ko, C.-W., Sridhara, R., Justice, R., & Pazdur, R. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0816 · Cited by 307
Spielmann, M., Roché, H., Delozier, T., Canon, J.-L., Romieu, G., Bourgeois, H., Extra, J.-M., Serin, D., Kerbrat, P., Machiels, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0946 · Cited by 298
Andersson, M., Lidbrink, E., Bjerre, K., Wist, E., Enevoldsen, K., Jensen, A. B., Karlsson, P., Tange, U. B., Sørensen, P. G., Møller, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8213 · Cited by 294
Zidan, J., Dashkovsky, I., Stayerman, C., Basher, W., Cozacov, C., & Hadary, A. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602738 · Cited by 282
Rimawi, M. F., Mayer, I. A., Forero, A., Nanda, R., Goetz, M. P., Rodriguez, A. A., Pavlick, A. C., Wang, T., Hilsenbeck, S. G., Gutierrez, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.8027 · Cited by 274
Gianni, L., Lladó, A., Bianchi, G., Cortes, J., Kellokumpu-Lehtinen, P.-L., Cameron, D. A., Miles, D., Salvagni, S., Wardley, A., Goeminne, J.-C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1661 · Cited by 262
Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer
Baselga, J. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-12 · Cited by 261
Curigliano, G., Viale, G., Bagnardi, V., Fumagalli, L., Locatelli, M., Rotmensz, N., Ghisini, R., Colleoni, M., Munzone, E., Veronesi, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0962 · Cited by 259
Valero, V., Forbes, J., Pegram, M. D., Pienkowski, T., Eiermann, W., von Minckwitz, G., Roche, H., Martin, M., Crown, J., Mackey, J. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6450 · Cited by 255
Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer
Perez, E. A., Suman, V. J., Davidson, N. E., Gralow, J. R., Kaufman, P. A., Visscher, D. W., Chen, B., Ingle, J. N., Dakhil, S. R., Zujewski, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.7045 · Cited by 255
Cortés, J., Fumoleau, P., Bianchi, G. V., Petrella, T. M., Gelmon, K., Pivot, X., Verma, S., Albanell, J., Conte, P., Lluch, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4207 · Cited by 249
HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
Perez, E. A., Reinholz, M. M., Hillman, D. W., Tenner, K. S., Schroeder, M. J., Davidson, N. E., Martino, S., Sledge, G. W., Harris, L. N., Gralow, J. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2154 · Cited by 233
Yen, L., You, X.-L., Al Moustafa, A.-E., Batist, G., Hynes, N. E., Mader, S., Meloche, S., & Alaoui-Jamali, M. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203685 · Cited by 230
Huober, J., Fasching, P. A., Barsoum, M., Petruzelka, L., Wallwiener, D., Thomssen, C., Reimer, T., Paepke, S., Azim, H. A., Ragosch, V., et al. (2012) · The Breast · doi:10.1016/j.breast.2011.07.006 · Cited by 223
Burstein, H. J., Keshaviah, A., Baron, A. D., Hart, R. D., Lambert‐Falls, R., Marcom, P. K., Gelman, R., & Winer, E. P. (2007) · Cancer · doi:10.1002/cncr.22885 · Cited by 214
Lin, N. U., Winer, E. P., Wheatley, D., Carey, L. A., Houston, S., Mendelson, D., Munster, P., Frakes, L., Kelly, S., Garcia, A. A., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2003-y · Cited by 195
Theriault, R. L., Carlson, R. W., Allred, C., Anderson, B. O., Burstein, H. J., Edge, S. B., Farrar, W. B., Forero, A., Giordano, S. H., Goldstein, L. J., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0098 · Cited by 192
Self-citationEstrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis
Pusztai, L., Viale, G., Kelly, C. M., & Hudis, C. A. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0059 · Cited by 182
von Minckwitz, G., Schwedler, K., Schmidt, M., Barinoff, J., Mundhenke, C., Cufer, T., Maartense, E., de Jongh, F. E., Baumann, K. H., Bischoff, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.021 · Cited by 181
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
Wang, L., Zhang, Q., Zhang, J., Sun, S., Guo, H., Jia, Z. Y., Wang, B., Shao, Z., Wang, Z., & Hu, X. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-248 · Cited by 162
Gong, Y., Booser, D. J., & Sneige, N. (2005) · Cancer · doi:10.1002/cncr.20987 · Cited by 158
Guarneri, V., Giovannelli, S., Ficarra, G., Bettelli, S. R., Maiorana, A., Piacentini, F., Barbieri, E., Dieci, M. V., D’Amico, R., Jovic, G., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0048 · Cited by 150
Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer
Bartsch, R., Wenzel, C., Altorjai, G., Pluschnig, U., Rudas, M., Mader, R. M., Gnant, M., Zielinski, C. C., & Steger, G. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9776 · Cited by 150
The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer
Lauring, J. D., Park, B. H., & Wolff, A. C. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0086 · Cited by 124
Self-citationBlumenthal, G. M., Scher, N. S., Cortazar, P., Chattopadhyay, S., Tang, S. W., Song, P., Liu, Q., Barnett-Ringgold, K., Pilaro, A. M., Tilley, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1212 · Cited by 123
Awada, A. H., Dirix, L. Y., Manso, L., Xu, B., Luu, T., Dieras, V. C., Hershman, D. L., Agrapart, V., Ananthakrishnan, R., & Starosławska, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds284 · Cited by 115
Schäller, G., Fuchs, I. B., Gonsch, T., Weber, J., Kleine-Tebbe, A., Klare, P., Hindenburg, H.-J., Lakner, V., Hinke, A., & Bangemann, N. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6826 · Cited by 99
Lipton, A., Leitzel, K., Ali, S. M., et al. (2005) · Cancer · doi:10.1002/cncr.21202 · Cited by 98
Baselga, J. M., Cortés, J., Im, S., Clark, E., Kiermaier, A. C., Ross, G., & Swain, S. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-s5-1 · Cited by 58
O'Regan, R. M., Özgüroğlu, M., André, F., Toi, M., Jérusalem, G., Wilks, S. T., Isaacs, C. J., Xu, B., Masuda, N., Arena, F. P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.505 · Cited by 58
Yamamoto, D., Iwase, S., Kitamura, K., Odagiri, H., Yamamoto, C., & Nagumo, Y. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0497-5 · Cited by 57
Hurvitz, S. A., Dirix, L. Y., Kocsis, J., Gianni, L., Lu, J., Vinholes, J., Song, C., Tong, B., Chu, Y., & Perez, E. A. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)71443-5 · Cited by 54
柏葉, 匡. (2007) · Mebio oncology · Cited by 14
Cited by
Li, X., Yang, C., Wan, H., Zhang, G., Feng, J., Zhang, L., Chen, X., Zhong, D., Lou, L., Tao, W., et al. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.01.021 · Cited by 227
Belgioia, L., Desideri, I., Errico, A., Franzese, C., Daidone, A., Marino, L., Fiore, M., Borghetti, P., Greto, D., & Fiorentino, A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.11.009 · Cited by 35
Sun, W. Y., Lee, D.-S., Park, J. H., Kim, O.-H., Choi, H. J., & Kim, S.-J. (2025) · Journal of Breast Cancer · doi:10.4048/jbc.2024.0262 · Cited by 12
“Approximately 20%–25% of breast cancer cases are HER2-positive [18,19].”
Metadata
- Authors
- Figueroa-Magalhães, M. C., Jelovac, D., Connolly, R. M., & Wolff, A. C.
- Venue
- The Breast
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 23
- Issue
- 2
- Pages
- 128-136
- ISSN
- 0960-9776 (ISSN-L)
- OpenAlex
- W2138977450
- Cited by
- 273
- References
- 87
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.